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Zero orderAbstract Conventional drug delivery system provides an immediate release of drug which does not
control the release of the drug and does not maintain effective concentration at target site for a
longer period of time. Hence to avoid the shortcomings there is development of various controlled
drug delivery systems. Among these osmotic drug delivery system (ODDS) utilizes the principle of
osmotic pressure and delivers drug dose in an optimized manner to maintain drug concentration
within the therapeutic window and minimizes toxic effects. ODDS releases drug at a controlled rate
that is independent of the pH and thermodynamics of dissolution medium. The release of drug from
ODDS follows zero order kinetics. The release of drug from osmotic system depends upon various
formulation factors such as solubility, osmotic pressure of the core components, size of the delivery
oriﬁce and nature of the rate controlling membrane. Controlled porosity osmotic pump (CPOP)
contains drug, osmogens, excipients in core and a coating of semipermeable membrane with water
soluble additives. In CPOP water soluble additives dissolve after coming in contact with water,
resulting in an in situ formation of a microporous membrane. The present study gives an idea about
osmosis, CPOP, components of CPOP and its evaluation.
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Oral route1 is a convenient route for the administration of var-
ious drugs because of low cost and ease of administration to
the patients. But conventional drug delivery system does not
control the release of drug and provides immediate release of
drug. The rate and extent of drug absorption from conven-
tional formulations change signiﬁcantly depending on factors
such as physicochemical properties of the drug, presence of
excipients, physiological factors such as presence or absenceof food, pH of gastrointestinal (GI) tract, GI motility2and so
on. To overcome these shortcomings researchers have focused
on the development of novel drug delivery system3 (NDDS).
Among various designs of NDDS available in the market
per oral controlled release system provides improved patient
compliance, convenience and reduction in ﬂuctuation in a
steady state plasma level.5 In Controlled drug delivery system
(CDDS) there is a maximum utilization of drug optimizing
reduction in total amount of dose and delivers short biological
half life of drugs.4 CDDS offers temporal and spatial control
Table 1 Osmotic agents with their osmotic pressure.44–46
S. No. Osmogents Osmotic
pressure (atm)
1. Adipic acid 8
2. Fumaric acid 10
3. Lactose 23
4. Mannitol 38
5. Potassium sulphate 39
6. Tartaric acid 67
7. Citric acid 69
8. Dextrose 82
9. Sorbitol 84
10. Xylitol 104
11. Potassium phosphate 105
12. Melanic acid 117
13. Sucrose 150
14. Lactose-dextrose 225
15. Potassium chloride 245
16. Lactose-sucrose 250
17. Fructose 355
18. Mannitol-fructose 415
19. Sucrose-fructose 430
20. Dextrose-fructose 450
21. Lactose-fructose 500
22. Mannitol-dextrose 225
23. Dextrose-sucrose 190
24. Mannitol-sucrose 170
25. Mannitol-lactose 130
26. Sodium phosphate monobasic H2O 28
27. Sodium phosphate dibasic anhydride 29
28. Sodium phosphate dibasic 7H2O 31
29. Sodium phosphate dibasic 12H2O 31
30. Sodium phosphate tribasic 12H2O 36
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(ODDS) is one of the most advanced drug delivery systems
that utilizes osmotic pressure as a driving force for controlled
delivery of drugs. The release of drug from osmotic system is
independent of presence and absence of food, pH of gastroin-
testinal (GI) tract, GI motility and hydrodynamic conditions
of body due to rate controlling semi permeable membrane.5
In ODDS the drug dose and dosing interval are optimized toTable 2 Criteria and speciﬁcations of controlled porosity
osmotic pump.35,67
Criteria Speciﬁcations
Plasticizer and ﬂux
regulating agent
0 to 50, generally 0.001 to 50 parts per 100
parts of wall material
Surfactants 0 to 40, generally 0.001 to 50 parts per 100
parts of wall material
Wall thickness 1 to 1000, generally 20 to 500 mm
Osmotic pressure Generally between 8 to 500 atm
Core size Between 0.05 mg to 5 g
Micro porous
structure
5 to 95% pores between 10 mm to 100 mm
diameter 0.1 to 60% generally 0.1 to 50%
by weight based on total weight of
excipients and polymer.maintain drug concentration within the therapeutic window.
ODDS delivers the drug at predetermined zero order rate for
a prolonged time period. So it is used as the standard dosage
form for constant drug delivery. ODDS provides a uniform
concentration of drug at the site of absorption and thus after
absorption allows maintenance of plasma concentration within
therapeutic range which minimizes side effects and reduces the
frequency of administration.6 When an osmotic system comes
in contact with water, water diffuses into the core through the
micro porous membrane setting up an osmotic gradient and
thereby controlling the release of the drug. Osmotic pressure
created due to imbibitions of ﬂuid from external environment
into the dosage form regulates the delivery of drug from osmo-
tic devices.7 Osmotic pressure is the pressure applied to the
higher concentrated solution side to prevent transport8 of
water across the semi permeable membrane. The rate of drug
delivery from osmotic system is directly proportional to the
osmotic pressure developed due to imbibitions of ﬂuids by
osmogen. The ODDS has high in vitro-in vivo correlation.
Hence osmotic drug delivery technique is most interesting
and widely acceptable among all other techniques.9 The
following review concentrates on controlled porosity osmotic
pump tablets of osmotic drug delivery systems.2. Osmotic drug delivery devices
Based on osmotic drug delivery devices10,11 design and the
state of use osmotic drug delivery system can be classiﬁed into
the following categories (see Table 1).
2.1. Implantable osmotic pump
An implantable osmotic pump which delivers drug to a patient
includes an osmotic engine, a substantially toroidal compart-
ment disposed at least partially around the osmotic engine
and a piston disposed within the compartment. The osmotic
engine is employed to cause the piston to travel within the
compartment and expel active ingredient contained within
the compartment when the pump is implanted in an aqueous
environment. Various types of implantable osmotic systems
include the Rose and Nelson pump,12 the Higuchi Theeuwes
pump,13 and the Higuchi Leeper pump14 and implantable min-
iosmotic pump includes the Alzet15 and Duros miniosmotic
pump.162.2. Oral osmotic pump
Oral osmotic pump pertains to an osmotic device for delivering
an active ingredient into the oral cavity of patients. The osmo-
tic device comprises a shaped semi permeable membrane sur-
rounding a compartment containing an active ingredient that
is insoluble to very soluble in an aqueous ﬂuid. The passage
through the semi permeable membrane connects the exterior
of the device with the compartment containing the active agent
for delivering the agent from the device into the oral cavity.
Based on the chamber the oral osmotic pump is classiﬁed into
single chamber osmotic pump e.g. elementary osmotic pump17
(EOP) and multi chamber osmotic pump such as push pull
osmotic pump18 (PPOP) and osmotic pump with nonexpand-
ing second chamber.19
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Recent advances include various speciﬁc types of osmotic
pump systems such as controlled porosity osmotic pump20
(CPOP), osmotic bursting osmotic pump21 (OBOP), Liquid
OROS/Liquid oral osmotic system22 e.g. L OROS hard cap,
L OROS soft cap and delayed liquid bolus delivery system,
telescopic capsule,23 OROS CT,24 sandwiched osmotic
tablets25 (SOTS), monolithic osmotic system,26 osmat,27 multi
particulate delayed release systems28 (MPDRS), pulsatile
delivery based on expandable oriﬁce,29 pulsatile delivery by a
series of stops30and lipid osmotic pump.31
3. Controlled porosity osmotic pump (CPOP)
Controlled porosity osmotic pump is an osmotic tablet in
which membrane contains water soluble leachable pore form-
ing agents. The coating of semi permeable membrane is done
by a suitable coating method. The pump can be designed as
single or multicompartment dosage form and the delivery sys-
tem comprises a core with the drug surrounded by a membrane
which has an asymmetric structure supported by a porous32
substructure. The membrane is permeable to water but imper-
meable to solute. Water soluble pore forming additives are dis-
persed throughout wall of the membrane. CPOP lacks aperture
to release the drugs, but drug release is achieved through the
pores which are formed in the semi permeable wall in situ dur-
ing the operation. When CPOP is exposed to water low levels
of water soluble additives are leached from polymer materials
that are permeable to water. The resulting sponge like struc-
ture is formed in the controlled porosity walls (see Table 2).
In this system the drug after dissolution inside the core is
delivered from the osmotic pump tablet by hydrostatic pres-
sure and diffusion through the pores incorporated in the micro
porous semi permeable membrane and controlling the release
of drug. The hydrostatic pressure is generated either by an
osmotic agent33 or by the drug itself or by a tablet component
after water is imbibed across the semi permeable membrane.
The rate of drug delivery depends upon factors such as water
permeability of the semi permeable membrane, osmotic pres-
sure of core formulation, thickness and total surface area of
coating.34 The designer can control all the factors and the for-
mulation will not change in physiological conditions. The rate
of ﬂow of water into the device can be expressed as given below
dv=dt ¼ Ak=hðdp dpÞ ð1Þ
where dv/dt is rate of ﬂow of water to the device, k and A are
membrane permeability and surface area of membrane respec-
tively, dp and dp are osmotic pressure difference and hydro-
static difference between inside and outside of the membrane
respectively.
4. Advantages of controlled porosity osmotic pump tablets33,35
(1) The release of drugs from controlled porosity osmotic
pump tablets follows zero order kinetics after an initial
lag.
(2) The delivery of drug may be delayed or pulsatile.
(3) The drug release is independent of physiological condi-
tions of the body, gastric pH, and drug and of hydrody-
namic condition.(4) The drug delivery provides high degree of in vitro in vivo
correlation.
(5) The drug release is higher than conventional drug deliv-
ery system.
(6) The release of drug is less affected by the presence of
food in gastrointestinal tract.
(7) The delivery rate of drug from CPOP is predictable and
programmable.
(8) There is no need of laser drilling because the holes are
formed in situ.
(9) The production in scale up is very easy.
(10) The stomach irritation problems are reduced because the
drug is delivered from the entire surface rather than sin-
gle delivery oriﬁce.
(11) It is useful for water soluble, partially water soluble and
water insoluble drugs.
5. Disadvantages of controlled porosity osmotic pump tablets35
(1) The method of preparation is very costly.
(2) Retrieval therapy is not controllable in case of unex-
pected adverse effects.
(3) There is a chance of dose dumping if the coating process
is not well controlled.
(4) There is a chance for the development of drug tolerance.
6. Drug release mechanism
When the controlled porosity osmotic pump tablets are in
aqueous environment the water soluble additives get dissolved
and form a micro porous structure in the coating membrane.
The pores formed in SPM may be continuous with micro por-
ous lamina, interconnected through tortuous paths of regular
and irregular shapes.36 Pore forming additives having a con-
centration range of 5%–95% produce pores with pore size
ranging from 10A˚ to 100 lm. This technology is applicable
for water soluble, partially water soluble and water insoluble
drugs. The semi permeable membrane forms a sponge like
structure when it is in contact with water. The water enters
through pores of semi permeable membranes and forms a solu-
tion of drug which is released through pores. The rate of water
inlet is depends on the type and concentration of osmogent
and the drug release depends upon hydrostatic pressure cre-
ated by inlet water, and the size and number of pores.37
Water is used as a solvent for different osmotic pump prin-
ciples for drug delivery system. All pumps deliver the solvent
ﬂow across the semi permeable membrane for actuation. The
solvent inﬂow through the membrane into the osmotic device
dissolves the drug which is used as an osmotic agent and dis-
places the saturated drug solution through outlets. The volume
ﬂow of solvent into the core reservoir is expressed in Eq. (2).
dv
dt
¼ A
h
Lðrdp dpÞ ð2Þ
where dv/dt is water ﬂux, A is area of the semi permeable mem-
brane, h is thickness of the membrane, dp and dp are the osmo-
tic and hydrostatic pressure difference between the inside and
outside of the system, L is mechanical permeability and r is the
reﬂection coefﬁcient. In case of an osmotic agent in a sealed
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sure can build up over time. For drug release applications open
release pore or multiple pores are essential which limit the
hydrostatic pressure due to the continuous drug ﬂow through
the release pore or pores. As a result of which the hydrostatic
pressure difference between the osmotic agent device and the
outlet area is deﬁned by the ﬂow resistance of the release pore
times the net ﬂow of solvent across the semi permeable mem-
brane. The effective drug release rate of the system through
the oriﬁce at a controlled rate is expressed in Eq. (3)
dm
dt
¼ dv
dt
C ð3Þ
where dm/dt is solute/drug delivery rate and C is the concentra-
tion of drug in dispersed ﬂuid.
Reﬂection coefﬁcient is taken to consideration when there is
leakage of drug through the membrane. The SPM which is per-
fect does not allow solute to pass through it and r is close to
unity. If the oriﬁce is sufﬁciently large the hydrostatic pressure
will be negligible which tends to zero. Hence the Eq. (2) becomes
dv
dt
¼ A
h
Lrdp ð4Þ
The osmotic pressure of gastrointestinal ﬂuids is negligible
as compared to that of core, hence p is replaced by dp and Lr
is replaced by a constant K. Hence the equation becomes
dv
dt
¼ A
h
Kp ð5Þ
Hence the pumping drug rate from the core can be
expressed as
dm
dt
¼ A
h
KpC ð6Þ
This fundamental equation38 is applicable to all osmotically
driven pumps as well as controlled porosity osmotic pump
tablets.
7. Basic components of controlled porous osmotic pump tablets
7.1. Drugs
The drug which is water soluble in nature can be designed in
this system only. The drugs having a short biological half life
(2–6 h), prolonged treatment drugs e.g. nifedipine,39 glipizide40
etc. and highly potent drugs can be designed for this system.
7.2. Osmotic components/osmogents
Osmotic agents maintain a concentration gradient41 across the
membrane which is essential for designing osmotic formula-
tions. During the penetration of biological ﬂuid into the CPOP
through semi permeable membrane, osmogens are dissolved in
the biological ﬂuid which builds up osmotic pressure inside the
pump and pushes medicament outside the pump through
delivery oriﬁce. They create a driving force for the uptake of
water and assist in maintaining drug uniformity in the
hydrated formulation. Osmogents42 are used in the fabrication
of osmotically controlled drug delivery systems and modiﬁed
devices for controlled release of relatively poorly water
insoluble drugs. Mostly polymeric osmogents are used for
design of CPOP. Osmogents generate osmotic pressure in theconcentrated solution ranging from 8 atm to 500 atm. These
osmotic pressures can produce high water ﬂows across the semi
permeable membrane. The rate of water ﬂow across the semi
permeable membrane is given by Eq. (7).
dv=dt ¼ AKp=h ð7Þ
where dv/dt is the rate of water ﬂow across the membrane, A
area of SPM, p is the osmotic pressure, K is the permeability
and h is the thickness.
7.2.1. Classification of osmogents43
7.2.1.1. Water-soluble salts of inorganic acids osmogents. The
examples of water soluble salts of inorganic acids osmogents
are magnesium chloride or sulphate, sodium chloride, sodium
sulphate, potassium chloride, sodium bicarbonate, sodium or
potassium hydrogen phosphate etc.
7.2.1.2. Organic polymeric osmogents. The examples of organic
polymeric osmogents are sodium carboxyl methylcellulose,
hydroxyl propyl methyl cellulose, hydroxyl methylcellulose,
methylcellulose, polyethylene oxide, polyvinyl pyrollidine,
polyacrylamides, carbopols etc.
7.2.1.3. Carbohydrates. The examples of carbohydrates which
are used for osmogents are arabinose, ribose, xylose, glucose,
fructose, galactose, mannose, sucrose, maltose, lactose, rafﬁ-
nose etc.
7.2.1.4. Water-soluble amino acids. The water soluble amino
acids which are used for osmogents are glycine, leucine, ala-
nine, me´thionineds glycine, leucine, alanine, me´thionine, etc.
7.2.1.5. Water soluble salts of organic acids osmogents. The
water soluble salts of organic acids osmogents are sodium
and potassium acetate, magnesium succinate, sodium ben-
zoate, sodium citrate, sodium ascorbate etc.
7.3. Semipermeable membrane (SPM)
Semi permeable membrane44 is also known as selectively per-
meable membrane or partially permeable membrane or differ-
entially permeable membrane.SPM is a membrane that allows
solvent and certain molecules or ions to pass through it by dif-
fusion or specialized facilitated diffusion. CPOP contains SPM
as the outer layer. The membrane is impermeable to the pas-
sage of drug and other ingredients present in the compart-
ments. The membrane is inert and maintains its dimensional
integrity to provide a constant osmotic pressure during the
drug delivery and is biocompatible with other ingredients of
the formulation.47 Cellulose acetate is mostly used for design-
ing of various CPOP tablets. The formation of SPM includes
cellulosic polymers such as cellulose ethers, cellulose esters
and cellulose ester-ether. The cellulosic polymers have a degree
of substitution of 0 to 3 on the anhydroglucose unit. The
degree of substitution is the number of hydroxyl groups pre-
sent on the anhydroglucose unit replaced by a substituting
group. The examples of these groups include cellulose acylate,
cellulose diacylate, cellulose triacylate, cellulose acetate, cellu-
lose diacetate etc. The other SPM forming polymers are group
consisting of acetaldehyde dimethyl cellulose acetate, cellulose
acetate ethyl carbamate, cellulose dimethylamino acetate,
polyamides, polyurethanes etc. The semi permeable membrane
Table 3 Angle of repose and its observations.
Angle of repose (h) Observation
<25 Free ﬂowing granules
25–30 Good ﬂow
300-40 Passable
>40 Poorly ﬂowing granules
200 C.K. Sahoo et al.is generally 200–300 lm thick to withstand the pressure within
the device.
7.3.1. Ideal property of semi permeable membrane48
(1) The material must have sufﬁcient wet strength and wet
modulus.
(2) The semi permeable membrane must have rigid dimen-
sional integrity during the operational time of the device.
(3) The membrane must have sufﬁcient water permeability
to retain water ﬂux rate in the desired range.
(4) The reﬂection coefﬁcient and leakiness of the osmotic
agent should approach the limiting value of unity.
7.4. Coating solvents
Coating solvents21 are suitable for making polymeric solutions
that are used for manufacturing the wall of osmotic device. It
includes inert organic and inorganic solvents. The solvents
used for coating solvents are methylene chloride, acetone,
methanol, ethanol, isopropylalcohol, butyl alcohol, ethyl acet-
ate, cyclohexane, carbon tetrachloride, water etc. The mixtures
of solvents49 include acetone-methanol(80:20), acetone-ethanol
(80:20), acetone-water(90:10), methylene chloride-methanol
(79:21), methylene chloride-methanol-water(75:22:3) etc.
7.5. Emulsifying agents
Emulsifying agents are added to wall forming material to pro-
duce an integral composition which is useful to make the wall
of the device. They regulate the surface energy of materials to
improve their blending47 into the composite and maintain their
integrity in the environment of use during the drug release per-
iod. The examples of emulsifying agents are polyoxyethyle-
nated glyceryl recinoleate, polyoxyethylenated castor oil
having ethylene oxide, glyceryl laureates, glycerol (sorbitan
oleate, stearate or laurate) etc.
7.6. Flux regulating agents
Flux regulating or ﬂux enhancing 50 or ﬂux decreasing agents
are used in wall forming materials to regulate the ﬂuid perme-
ability of ﬂux through wall. This agent can be used to increase
or decrease the liquid ﬂux. The ﬂux regulating agents may be
hydrophilic substances and hydrophobic substances. The
hydrophilic substances such as polyethylene glycols, polyhy-
dric alcohols, polyalkylene glycols increase the ﬂux whereas
hydrophobic substances such as phthalates substituted with
alkyl or alkoxy (diethyl phthalate or dimethoxyethyl phtha-
late) decrease the ﬂux.
7.7. Wicking agents
Wicking agent has the ability to draw water into the porous
network of delivery device. The wicking agent may be swella-
ble or nonswellable in nature. It has the ability to undergo
physisorption with water. Physisorption is the form of absorp-
tion in which the solvent molecules can loosely adhere to sur-
faces of the wicking agent via vanderwaal’s interactions
between the surface of the wicking agent and the absorbedmolecule. The wicking agent’s function51 is to carry water to
the surfaces inside the core of the device and create channels
or a network of increased surface area. The examples of wick-
ing agents are colloidal silicon dioxide, kaolin, titanium diox-
ide, alumina, niacinamide, polyvinyl pyrrolidone, bentonite,
sodium lauryl sulphate etc.
7.8. Plasticizers
Plasticizer is used to lower the temperature in phase transition
of the wall and also increase the workability, ﬂexibility and
permeability of the ﬂuids. The ranges of plasticizers or mixture
of plasticizers are between 0.01 parts to 50 parts which are
incorporated into 100 parts of wall forming materials.52 Suita-
ble solvents are used having high degree of solvent power for
materials and compatible with the materials over both the pro-
cessing and the temperature ranges to remain in the plasticized
wall imparting ﬂexibility to the material. The examples of plas-
ticizers are phthalates (dibenzyl, dihexyl, butyl, octyl), triace
tin,epoxidizedtallate,triisoctyltrimellitate,alkyladipates,citrate
s,acetates,propionates,glycolates,myristates,benzoates,haloge
nated phenyls etc.
7.9. Pore forming agents
The pore forming agents53 form micro porous structure in the
membrane due to their leaching during the operation of the
system usually used for poorly water soluble drugs. The pores
may be formed in the wall before operation of the system by
gas formation by volatilization of components or by chemical
reactions in polymer solution which creates pores in the wall.
The pore formers may be inorganic and organic in nature.54
The examples of pore forming are alkaline metal salts such
as sodium chloride, sodium bromide, potassium chloride,
potassium sulphate, potassium phosphate etc, alkaline earth
metals such as calcium chloride, calcium nitrate etc, carbohy-
drates such as sucrose, glucose, fructose, mannose, lactose,
sorbitol, mannitol, diols, polyols etc.
7.10. Barrier layer formers
The function of barrier former55 is to restrict water entry into
certain parts of the delivery system and to separate the drug
layer from the osmotic layer. The examples of barrier layer
formers are high density polyethylene, wax, rubber etc.
8. Specifications of controlled porosity osmotic pump
9. Compatibility studies
9.1. Fourier transform infrared spectroscopy (FTIR)
The use of FTIR technique allows pointing out the implication
of the different functional groups of drug and excipients by
Table 5 Hausner’s ratio and its ﬂow types.
Hausner’s ratio Flow type
1.2 Free ﬂowing granules
>1.6 Poorly ﬂowing granules
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the absorbance bands. In this method individual samples56 as
well as the mixture of drug and excipients were ground
and mixed thoroughly with potassium bromide (1:100) for
3–5 mins in a mortar and compressed into disc by applying
pressure of 5 tons for 5 mins in hydraulic press. The pellet
was kept in the sample holder and scanned from 4000 to
400 cm1 in FTIR spectrophotometer. Then the characteristics
peaks57 of all samples as well as mixtures were obtained. Then
the peaks of optimized58 formulation were compared with pure
drug and excipients. If there was no interaction between the
peaks of drug and excipients of optimized formulation then
it was said to be compatible.
9.2. Differential scanning calorimetry (DSC)
The compatibility of drug with the excipients used for formula-
tion development was tested using differential scanning
calorimetry.58 Physical mixtures of drug and individual excipi-
ents in the ratio of 1:1were taken and examined inDSC. Individ-
ual samples as well as physical mixture of drug and excipients
were weighed to about 5 mg in DSC pan. The sample pan was
crimped for effective heat conduction and scanned in the
temperature range of 50–300 C. Heating rate of 20 C min1
was used and the thermogram obtained was reviewed for
evidence of any interactions. Then the themograms59 were
compared with pure samples versus optimized formulation.
10. Evaluation of osmotic pump tablets
10.1. Precompression parameters of osmotic pump tablets
10.1.1. Angle of repose (h)
The angle of repose test is very sensitive to the method used to
create the heap. Angle of repose may be determined by heap60
shape measurement. By using the classical method angle of
repose can be measured. The diameter of powder heap is mea-
sured and angle of repose is calculated using the following
equation
tan h ¼ 2h=d ð8Þ
h ¼ tan1 ð2h=dÞ ð9Þ
where h is the angle of repose, h is the height of heap in cm and
d is the diameter of the circular support in cm. It is shown in
Table 3. Angle of repose can be observed accurately by placing
an initialization tube with an internal diameter equal to sup-
port diameter on the support. After manually ﬁlling the tubeTable 4 Relationship between powder ﬂowability and %
compressibility range.
% compressibility index Flow type
5–15 Excellent ﬂow (free ﬂowing granules)
12–16 Good
18–21 Fair (powdered granules)
23–28 Poor (very ﬂuid powders)
28–35 Poor (ﬂuid cohesive powders)
35–38 Very poor (ﬂuid cohesive powders)
>40 Extremely poor (cohesive powders)with the sample of powder the initialization tube goes up at
a constant speed of 5 mm/s. As a result of which the powder
ﬂows from the tube to form a heap on the cylindrical support.
This support rotates slowly around its axis. A CCD camera61
takes pictures of the heap for different orientations. To get the
results presented in the next Section 8 images separated by a
rotation of 22.5 were recorded. In this way all the geometrical
information was extracted. From each picture of the heap
algorithm ﬁnds the position of interface powder/air by image
analysis. The angle of repose (h) is the angle of the isosceles tri-
angle which has the same surface area as the heap. The isosce-
les triangle corresponds to the ideal heap shape.
10.1.2. Bulk density (eb)
Bulk density62 is determined by pouring the granules into a
graduated cylinder. The bulk volume (Vb) and mass (m) of
the granules are determined. The bulk density is calculated
by using the following formula.
Bulk density ðebÞ¼Mass of granulesðmÞ=Bulk volume of granulesðVbÞ
ð10Þ10.1.3. Tapped density (et)
The measuring cylinder containing a known mass of granules
blend is tapped 1000 times for a ﬁxed time. The minimum vol-
ume occupied in the cylinder (Vt) and mass of the granules (m)
are measured. The tapped density63 is measured by using the
following formula.
Tapped density ðetÞ ¼Mass of granules ðmÞ=Tapped volume
of granules ðVbÞ ð11Þ10.1.4. Compressibility index (Carr’s index)
The compressibility index64 determines the ﬂow property char-
acteristics of granules developed by Carr. The percentage com-
pressibility of granules is a direct measure of the potential
powder arch and stability. The Carr’s index can be calculated
by the following formula
% Carr’s index ¼ et  eb
et
 100 ð12Þ
where et is the tapped density of granules and eb is bulk density
of granules. It is represented in Table 4.Table 6 USP: speciﬁcations for weight variation of tablets.
Average weight of tablets
(mg)
Maximum percentage diﬀerence
allowed
130 or less ±10
130 to 324 ±7.5
More than 324 ±5
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Hausner’s ratio59 is used for the determinationof ﬂowproperties
of granules. The ratio can be calculated by taking the ratio of
tapped density to the ratio of bulk density. It is shown inTable 5.
10.2. Postcompression parameters of osmotic pump tablets
10.2.1. Thickness
The thickness65 of individual tablets is measured by using ver-
nier caliper which gives the accurate measurement of thickness.
It provides information of variation of thickness between osmo-
tic pump tablets.Generally the unit for thicknessmeasurement is
mm. The limit of the thickness deviation of each tablet is ±5%.
10.2.2. Hardness
The hardness66 of tablets can be determined by using
Monsanto hardness tester and measured in terms of kg/cm2.
10.2.3. Friability
Friability67 of tablets was performed in a Roche friabilator.
Ten tablets were initially weighed (W0) together and then
placed in the chamber. The friabilator was operated for 100
revolutions and the tablets were subjected to the combined
effects of abrasion and shock because the Plastic chamber car-
rying the tablets drops them at a distance of six inches with
every revolution. The tablets are then dusted and reweighed
(W).The percentage of friability was calculated using the fol-
lowing equationTable 7 Patents on controlled porosity osmotic pump tablets.
S. No. Patent No. Title
1. EP0169105 Controlled porosity osmotic pump
2. US5672167 Controlled release osmotic pump
3. WO1994001093 Controlled porosity osmotic enalpril pump
4. EP0309051 Controlled porosity osmotic pump
5. CA1320885 Controlled porosity osmotic pump
6. WO2001032149 Osmotic controlled release drug delivery
device
7. US8109923 Osmotic pump with remotely controlled
pressure generation
8. US20100291208 Controlled porous osmotic pump tablets of
high permeable drugs and the preparation
process thereof
9. WO2010081286 Timing controlled release porous tablet of
diltiazem hydrochloride and the preparation
method thereof.
10. EP2085078 Controlled porosity osmotic pump tablets o
high permeable drugs and preparation
method thereof
11. US5458887 Controlled release tablet formulation
12. US4687660 Pharmaceutical delivery system
13. US4880631 Controlled porosity osmotic pump
14. US4968507 Controlled porosity osmotic pump
15. US4851228 Multiparticulate controlled porosity osmoti
pump
16. US6753011 Combined diﬀusion/osmotic pumping drug
delivery system% Friability ¼ F ¼ 1W0
W
 
 100 ð13Þ
where,W0 andW are the weight of the tablets before and after
the test respectively. The limit for percentage of friability is
between 0.5% and 1%.
10.2.4. Weight variation
The weight variation test68 is done by weighing 20 tablets indi-
vidually calculating the average weight and comparing the
individual tablet weights to the average. The percentage weight
deviation was calculated and then compared with USP speciﬁ-
cations. The tablets meet the USP test if not more than 2
tablets are outside the percentage limit and if no tablet differs
by more than 2 times the percentage limit. It is shown in
Table 6.
The weight variation ofnthtablet ¼ ðjw wnjÞ
w
 100% ð14Þ
where weight of tablets are w1, w2, w3,...wn..., w20.and average
weight of the tablets = w
10.2.5. Disintegration test
In disintegration test67 apparatus disintegration time of tablets
is measured by placing tablets in each tube and the basket rack
assembly is positioned in a 1-litre beaker of water or simulated
gastric ﬂuid or simulated intestinal ﬂuid at 37 C± 2 C such
that the tablet remains 2.5 cm from the bottom of the beaker.Publication
date
Inventors Ref.
No.
Jan.22,1986 Gaylen M Zentner, Gerald S Rork,
Kenneth J Himmnelstein
73
Sept.30,1997 Amulya L Athayde, Rolf A Faste, C
Russell Horres Jr, Thomas P Low
74
Jan.20,1994 John L Haslam, Gerald S Rork 75
Mar.11,1992 John L Haslam, Gerald S Rork 76
Aug.3,1993 John L Haslam, Gerald S Rork 77
May 10,2001 Laura A Debusi, Stephen B Ruddy,
David E Storey
78
Feb.7,2012 LE Hood, MY Ishikawa, EKY Jung,
R Langer, T Clarence, TLL Wood,
VYH Wood
79
Nov.18,2010 Jingang Wang, Haisong Jiang 80
Jul.22,2010 Haisong Jiang, Jingang Wang 81
f Nov.20,2013 Jingang Wang, Haisong Jiang 82
Oct.17,1995 Chih Ming Chen, Charles SL Chiao,
Jose Suarez
83
Aug.18,1987 Richard W Baker, James W Brooke 84
Nov.14,1989 John L Haslam, Gerald S Rock 85
Nov.6,1990 Gaylen M Zentner, Gerald S Rork,
Kenneth J Himmnelstein
86
c Jul.25,1989 Gaylen M Zentner, Kenneth J
Himmnelstein, Gerald S Rork
87
Jan.22,2004 Joaquina Faour 88
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distance of 5 to 6 cm at a frequency of 28 to 32 cpm (cycles
per minute). USP disintegration test will be passed if all the
tablets disintegrate and the particles are passed through the
#10 mesh screen within the speciﬁed time.
10.2.6. Uniformity of drug content test
In this USP method 10 dosage units are individually assayed
for their content according to the method described in the indi-
vidual monograph. Unless otherwise stated in the monograph
the requirements for content uniformity are met if the amount
of active ingredient in each dosage unit lies within the range of
85–115% of the label claim and standard deviation is less than
6%.If one or more dosage units do not meet these criteria
additional tests as prescribed in the USP are required.69
10.2.7. In vitro dissolution studies
In vitro dissolution70 study is performed by using USP Type I
Apparatus (Basket type). The tablet is kept in 900 ml of disso-
lution ﬂuid phosphate buffer of pH 7.4 or 0.1 N HCl or simu-
lated gastric ﬂuid with a stirrer rotating at a speciﬁed r.p.m and
maintaining the temperature at 37 ± 0.5 C of dissolution
media. 5 ml of samples withdrawn at different time intervals
were replaced with fresh medium and analysed in UV–Visible
spectrophotometer for estimation of absorbance taking a suit-
able blank solution. Finally the drug release rate is calculated
using a suitable equation.
10.2.8. Scanning electron microscopy (SEM)
In order to observe the mechanism of drug release71 from the
developed formulations surface coated tablets before and after
dissolution studies were examined using a scanning electron
microscope. Membranes were dried at 45 C for 12 h and
stored between sheets of wax paper in a desiccator until exam-
ination. The samples (membranes) were ﬁxed on a brass stub
using a double sided tape and then gold coated in vacuum
by a sputter coater. Scans were taken at an excitation voltage
of 20KV in SEM ﬁtted with ion sputtering device. The surface
morphology72 of coated membrane of optimized formulation
ﬁlm coating before and after dissolution was examined and
by comparing the porous morphology the capability of poro-
gen and drug release can be evaluated.
11. Patents on controlled porosity osmotic pump tablets
In recent years signiﬁcant attention has been focused on the
development of various types of osmotic drug delivery system.
Currently many pharmaceutical companies have interest to
patent osmotic drug delivery systems. Many patents have come
under the name of controlled porosity osmotic pump. It is
explained in Table 7.
12. Conclusion
Controlled porosity osmotic pump tablets utilize the principle
of osmotic pressure for drug delivery system. The drug delivery
from CPOP system is independent of the physiological factors
of gastrointestinal tract. By optimizing various formulation
factors such as solubility, osmotic pressure of core components
and nature of rate controlling membrane the drug delivery canbe controlled. The release of drug follows zero order kinetics
and is safer than conventional dosage forms.13. Conflict of interest
We declare that we have no conﬂict of interest.References
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